© 2017 Evestra, Inc.

Evestra is conducting research and product development in a number of important women’s healthcare areas, including among others, indications such as endometriosis, fibroids, fertility control (FC), hormone replacement therapy (HRT), and overactive bladder (OAB). Evestra’s product pipeline includes pre-clinical products and clinical stage products. Our lead product candidate is EVE116, a second generation vaginal ring contraceptive, which will be undergoing Phase II clinical studies in Europe in early 2018. We expect to bring the first products to market in 2019 via collaborations with Gedeon Richter and Glenmark.

Evestra seeks to contribute to the health and well-being of women throughout the world through the discovery, development, and commercialization of innovative, next generation women’s healthcare technologies that address unmet needs. In particular, we have sought to identify, develop, and commercialize “woman-controlled” health product candidates that enable women to take direct control and ownership in managing their fertility and overall sexual health.

Evestra’s competitive advantage is based on its founders’ and scientific advisors’ experience in pharmaceutical R&D in general, and of hormonal steroidal drugs in particular, combined with a proven track record in commercializing women’s healthcare products. Our focus is to provide a solid return to our investors based on an array of differentiated women's healthcare products.

Evestra’s goal is to become a market leader in women healthcare area by driving innovation. To achieve our goals in a quickly changing marketplace, Evestra will continue to maintain  flexibility by expanding partnerships and ensure optimal ratio of internal and external capabilities.


Founded in 2008, Evestra, Inc. (“Evestra” or the “Company”) is a biopharmaceutical research and development company with a therapeutic focus in women’s healthcare. Based in San Antonio, Texas with additional offices in Europe, Evestra is a spin-off of the Organic Chemistry Department of Texas Biomedical Research Institute (“TXBiomed”).